Skip to Content

Acquired Platelet Dysfunction


David J. Kuter

, MD, DPhil, Harvard Medical School

Last full review/revision Jun 2020| Content last modified Jun 2020

Acquired platelet dysfunction, which is common, may result from aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), or systemic disorders.

(See also Overview of Platelet Disorders.)

Acquired abnormalities of platelet function are very common. Causes include

  • Drugs
  • Systemic disorders
  • Cardiopulmonary bypass

Acquired platelet dysfunction is suspected and diagnosed when unusual or prolonged bleeding is observed and other possible diagnoses (eg, thrombocytopenia, coagulation abnormalities) have been eliminated. Platelet aggregation studies are unnecessary.


Aspirin, other NSAIDs, inhibitors of the platelet P2Y12 adenosine diphosphate (ADP) receptor (eg, clopidogrel, prasugrel, ticagrelor), and glycoprotein IIb/IIIa receptor inhibitors (eg, abciximab, eptifibatide, tirofiban) may induce platelet dysfunction. Sometimes this effect is incidental (eg, when the drugs are used to relieve pain and inflammation) and sometimes therapeutic (eg, when aspirin or the P2Y12 inhibitors are used for prevention of stroke or coronary thrombosis).

Aspirin and NSAIDs prevent cyclooxygenase-mediated production of thromboxane A2. This effect can last 5 to 7 days. Aspirin modestly increases bleeding in healthy people but may markedly increase bleeding in older patients and those with underlying platelet dysfunction or a severe coagulation disturbance (eg, patients receiving heparin, patients with severe hemophilia). Clopidogrel, prasugrel, and ticagrelor all can markedly reduce platelet function and increase bleeding.

A number of other drugs can also cause platelet dysfunction (1).

Systemic disorders

Many disorders (eg, myeloproliferative neoplasms, myelodysplastic disorders, uremia, macroglobulinemia, multiple myeloma, cirrhosis, systemic lupus erythematosus) can impair platelet function.

Uremia prolongs bleeding via unknown mechanisms. If bleeding is observed clinically in uremic patients, bleeding may be reduced with vigorous dialysis, cryoprecipitate administration, or desmopressin infusion. If necessary, increasing the hemoglobin concentration to > 10 g/dL by transfusion or by giving erythropoietin also reduces bleeding.

Cardiopulmonary bypass

As blood circulates through a pump oxygenator during cardiopulmonary bypass, platelets may become dysfunctional, prolonging bleeding. The mechanism appears to be activation of fibrinolysis on the platelet surface with resultant loss of the glycoprotein Ib/IX binding site for von Willebrand factor. Regardless of platelet count, patients who bleed excessively after cardiopulmonary bypass are often transfused with platelets. Giving an antifibrinolytic agent during bypass may preserve platelet function and reduce the need for transfusion.

General reference

  • Scharf RE: Drugs that affect platelet function. Semin Thromb Hemost 38(8): 865–883, 2012. doi: 10.1055/s-0032-1328881 Epub 2012 Oct 30.

Drugs Mentioned In This Article

Drug Name Select Trade
eptifibatide INTEGRILIN
desmopressin DDAVP, STIMATE
clopidogrel PLAVIX
ticagrelor BRILINTA
abciximab REOPRO
tirofiban AGGRASTAT
prasugrel EFFIENT
aspirin No US brand name

Copyright © 2022 Merck & Co., Inc., known as MSD outside of the US, Kenilworth, New Jersey, USA. All rights reserved. Merck Manual Disclaimer